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A B S T R A C T
Primary coenzyme Q10 deﬁciency-7 is caused by homozygous or compound heterozygous mutations in the
COQ4 gene. Until now 12 patients have been reported, most presenting with a lethal infantile phenotype with
encephalopathy, epilepsy and cardiomyopathy. We report on a new phenotype of COQ4 deﬁciency: a childhood




Coenzyme Q10 (ubiquinone; CoQ10, EC 206–147-9) is essential for
mitochondrial respiratory chain electron transport [1,2]. Primary
CoQ10 deﬁciency is caused by mutations in genes of the COQ10 bio-
synthetic pathway. Primary coenzyme Q10 deﬁciency-7 (COQ10D7,
MIM 616276) is caused by homozygous or compound heterozygous
mutation in the COQ4 gene (MIM 612898). Symptoms include early
onset encephalomyopathy, cerebellar ataxia and nephropathy [3]. A
ﬁrst patient with CoQ10 deﬁciency due to COQ4 haploinsuﬃciency was
published in 2012 [4]. So far a total of 12 patients with compound
heterozygous or homozygous COQ4 variants have been reported, most
(11/12) patients presented with a lethal infantile phenotype with en-
cephalopathy, epilepsy and cardiomyopathy [5–7]. We report on a new
phenotype of COQ4 deﬁciency: a childhood onset spinocerebellar
ataxia with stroke-like episodes.
2. Patients and methods
The family pedigree is shown in Fig. 1: V-3 is patient 1 and V-4 is
patient 2. Patient V-3 and V-4 have four healthy siblings and one
younger brother with a complex constellation of congenital abnormal-
ities not caused by mutations in the COQ4 gene.
Patient 1 is the 15 year old third child of consanguineous parents.
His early psychomotor development was abnormal with delayed speech
development. He developed a “tremor” at the age of four years. Physical
examination was otherwise unremarkable. There were no dysmorphic
features, no skin abnormalities and no hepatosplenomegaly. Brain MRI
at age 5 revealed a suspected tectal glioma. He was treated with
radiotherapy and the lesion has been stable since age 10. However,
ambulation progressively deteriorated, and he became wheelchair de-
pendent around age 12. On neurological examination there was dys-
arthria, spastic tetraparesis and prominent ataxia of upper and lower
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limbs. He developed tonic-clonic seizures treated with carbamazepine
at age 12. Cognitive development was abnormal (TIQ 60), necessitating
special education.
Patient 2 is the 14 year old sister of patient 1. After a normal early
development she developed tonic clonic seizures at age 9, treated with
carbamazepine, and a “tremor” of the hands at age 10. Her IQ was
around 55–60. Walking became diﬃcult, with frequent falls. On ex-
amination she had a spinocerebellar syndrome like her brother, with a
normal general physical examination. MRI of the brain revealed a ca-
vernoma in de left parietal lobe, but no other abnormalities. General
laboratory tests were normal, speciﬁcally creatinine. At age 13 years
she was admitted to our hospital because of severe headache, vomiting,
and a decreased consciousness. On examination there was a right sided
hemi-anopsia. An MRI scan identiﬁed a lesion in the left occipital lobe
on T2 and FLAIR images, with clear diﬀusion restriction (Fig. 1). Within
24 h she made a full recovery and follow-up imaging at 3months
showed normalization on MRI.
Since these siblings both developed a progressive spinocerebellar
syndrome, a genetic cause was suspected. Whole exome sequencing
(speciﬁcs can be requested from the authors) revealed a homozygous
variant in the COQ4 gene (NM_016035.3: c.230C > T (p.Thr77Ile)) in
patient 2 which was also identiﬁed in patient 1 by targeted sequencing.
Thr77 concerns an evolutionary conserved amino acid located in a
conserved region in orthologues (up to Baker's yeast) and this variant is
not reported in healthy individuals (ExAC databasePMID: 27535533).
The segregation pattern in this family, with both parents being carriers
and the identiﬁcation of the same homozygous COQ4 variants in the
aﬀected sibling, supports pathogenicity of this variant. Functional stu-
dies in cultured skin ﬁbroblasts of patient 2 demonstrated decreased
levels of CoQ10 (0.26 nmol/U CS; reference range 0.77–1.61 (mean
1.19); n=30), as detected by nanoHPLC-ECD. This proves that the
patient has a coenzyme Q10 deﬁciency, supporting the notion that the
variant in the COQ4 gene is pathogenic.
After the diagnosis at age 13 and 11 respectively, CoQ10 supple-
mentation in a dose of 1000mg once daily was initiated for both sib-
lings. The 6min walk test was stable over the period of a year. Patient 2
developed a second stroke-like episode at age 14.
3. Discussion
This is the ﬁrst report of a childhood-onset spinocerebellar syn-
drome with stroke-like episodes caused by COQ4-deﬁciency and is
diﬀerent from the lethal infantile presentation described earlier [5–7].
Patient S5 reported by Brea-Calvo [5] is most comparable to our pa-
tients with progressive motor deterioration from age 10months, spastic
ataxic gait at age 3, wheelchair dependency, epilepsy and progressive
deterioration. However, other primary CoQ10 deﬁciencies have been
associated with a late-onset ataxic phenotype, like ARCA2 (due to
mutations in the ACDK3 gene) [8]. Stroke-like episodes were also re-
ported in patients with ADCK3 mutations and in patients with infantile
encephalomyopathy and nephropathy with CoQ10 deﬁciency [8,9].
This further supports that these symptoms are related to CoQ10 deﬁ-
ciency.
The majority of previously reported patients with CoQ10 deﬁciency
demonstrated cerebellar atrophy on imaging [8] but this was not seen
in our patients. It is possible that this feature will develop later in life.
Imaging did reveal a tectal glioma in patient 1 but this seems unrelated
to the COQ4 mutation. Other primary CoQ10 deﬁciencies were asso-
ciated with cardiac failure, but echocardiography demonstrated no
cardiomyopathy in our patients. Except for the stroke-like episodes our
patients did not deteriorate rapidly, it is unclear if this is due to CoQ10
supplementation. In other patients, a beneﬁcial eﬀect of CoQ10 sup-
pletion was reported [8,9]. However, follow-up on our patients is not
yet long enough to establish that there is no disease progression. Also,
patient 2 developed a new stroke like episode while being treated with
CoQ10. It seems therefore that CoQ10 suppletion does not prevent (all)
stroke-like episodes in this disorder.
With whole exome sequencing becoming routine in the evaluation
of neurodegenerative disorders, more cases will be diagnosed in the
near future and the clinical spectrum of COQ4 deﬁciency will be more
clearly deﬁned. Functional studies in cultured ﬁbroblasts from a skin
biopsy can provide strong supportive evidence for pathogenicity of
unknown variants in genes encoding enzymes of the coenzyme Q10
biosynthesis pathway, as illustrated in these cases. Treatment with
CoQ10 can be considered, though clear evidence of eﬃcacy in these
slowly progressive ataxic phenotypes is still lacking.
Fig. 1. On the right side of the ﬁgure is the family pedigree. On the left side the MRI scan from patient 2 (top row MRI at the time of the ﬁrst stroke like episode,
bottom row 3months later). There is a lesion in the left occipital lobe (indicated by the white arrow) with increased signal on FLAIR (A) and low signal on T1-
weighted images (B). There is patchy enhancement after gadolinium administration (C) and is abnormal signal intensity on DWI (D) and ADC (E). There is complete
normalization on a follow-up scan about 3months later.
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